Effects of Indomethacin on Patent Ductus Arteriosus in Neonates with Genetic Disorders and/or Congenital Anomalies

Abstract

Objectives The study aimed to evaluate the effectiveness of intravenous indomethacin (IND) therapy for patent ductus arteriosus (PDA) in neonates with genetic disorders and/or congenital anomalies soon after birth.

Study Design A total of 301 neonates with a genetic disorder and/or congenital anomalies and with a gestational age of ≥35 weeks were admitted during the study period. Eighty-five neonates with 56 genetic disorders (30 cases of trisomy 21, 10 cases of trisomy 18, and 16 others) and 29 congenital anomalies, and with clinical symptoms received intravenous IND therapy. The management methods were similar to those used for PDA in low-birth-weight infants.

Results IND therapy had a clinical benefit at a high rate of 79% in these patients (90% and 70% in neonates with trisomies 21 and 18, respectively), including complete closure of the PDA in 52% of the patients. Although oliguria was observed in 43 infants (51%) and slight gastrointestinal bleeding was observed in 12 (14%), no infants had severe complications such as intracranial bleeding.

Conclusions IND therapy is an effective treatment option before considering surgery for PDA in neonates with genetic disorders and/or congenital anomalies. This therapy may reduce the difficulty of treatment in the acute stage among these neonates.

Keywords

patent ductus arteriosus (PDA) - indomethacin - chromosome abnormality - trisomy 21 - trisomy 18

• References

• 1 Fyler DC. Patent ductus arteriosus. In: Fyler DC, , ed. Nadas' Pediatric Cardiology. Philadelphia, PA: Hanley & Belfus; 1992: 525-534
• 2 Nora JJ. Multifactorial inheritance hypothesis for the etiology of congenital heart diseases. The genetic-environmental interaction. Circulation 1968; 38: 604-617
• 3 Guarnieri GF, Laforgia N, Mautone A, Balducci G. Delayed closure of the ductus arteriosus in term newborns with congenital hypothyroidism: effect of L-thyroxine therapy. Pediatr Cardiol 2008; 29: 183-184
• 4 Martin RP, Banner NR, Radley-Smith R. Familial persistent ductus arteriosus. Arch Dis Child 1986; 61: 906-907
• 5 Giroud JM, Jacobs JP. Evolution of strategies for management of the patent arterial duct. Cardiol Young 2007; 17 (Suppl. 02) 68-74
• 6 Papageorgiou A, Bardin CL. The extremely-low-birth weight infant. In: Avery GB, Fletcher MA, MacDonald MG, , eds. Neonatology. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 1999: 445-472
• 7 Takami T, Yoda H, Kawakami T , et al. Usefulness of indomethacin for patent ductus arteriosus in full-term infants. Pediatr Cardiol 2007; 28: 46-50
• 8 Amoozgar H, Ghodstehrani M, Pishva N. Oral ibuprofen and ductus arteriosus closure in full-term neonates: a prospective case-control study. Pediatr Cardiol 2010; 31: 40-43
• 9 Clyman RI, Hardy P, Waleh N , et al. Cyclooxygenase-2 plays a significant role in regulating the tone of the fetal lamb ductus arteriosus. Am J Physiol 1999; 276 (3 Pt 2) R913-R921
• 10 Wu GR, Jing S, Momma K, Nakanishi T. The effect of vitamin A on contraction of the ductus arteriosus in fetal rat. Pediatr Res 2001; 49: 747-754
• 11 Gittenberger-de Groot AC. Persistent ductus arteriosus: most probably a primary congenital malformation. Br Heart J 1977; 39: 610-618
• 12 Rudolph AM. The ductus arteriosus and persistent patency of the ductus arteriosus. In: Rudolph AM, , ed. Congenital Diseases of the Heart. 2nd ed. Armonk, NY: Futura; 2001: 155-196
• 13 Bouayad A, Kajino H, Waleh N , et al. Characterization of PGE2 receptors in fetal and newborn lamb ductus arteriosus. Am J Physiol Heart Circ Physiol 2001; 280: H2342-H2349
• 14 Coceani F, Kelsey L, Seidlitz E. Evidence for an effector role of endothelin in closure of the ductus arteriosus at birth. Can J Physiol Pharmacol 1992; 70: 1061-1064
• 15 Heymann MA, Rudolph AM. Effects of acetylsalicylic acid on the ductus arteriosus and circulation in fetal lambs in utero. Circ Res 1976; 38: 418-422
• 16 Yokoyama U, Minamisawa S, Quan H , et al. Chronic activation of the prostaglandin receptor EP4 promotes hyaluronan-mediated neointimal formation in the ductus arteriosus. J Clin Invest 2006; 116: 3026-3034
• 17 Momma K, Toyono M. The role of nitric oxide in dilating the fetal ductus arteriosus in rats. Pediatr Res 1999; 46: 311-315
• 18 Watanabe K, Tomita H, Ono Y, Yamada O, Kurosaki K, Echigo S. Intravenous indomethacin therapy in infants with a patent ductus arteriosus complicating other congenital heart defects. Circ J 2003; 67: 750-752
• 19 Vandekerckhove K, Macrae D, Slavik Z. Nonsurgical treatment of patent arterial duct in term neonates with congenital heart disease: the role of intravenous indomethacin. Pediatr Cardiol 2005; 26: 698-699
• 20 Weijerman ME, van Furth AM, Vonk Noordegraaf A, van Wouwe JP, Broers CJ, Gemke RJ. Prevalence, neonatal characteristics, and first-year mortality of Down syndrome: a national study. J Pediatr 2008; 152: 15-19
• 21 Bittles AH, Bower C, Hussain R, Glasson EJ. The four ages of Down syndrome. Eur J Public Health 2007; 17: 221-225
• 22 Rasmussen SA, Wong LYC, Yang QY, May KM, Friedman JM. Population-based analyses of mortality in trisomy 13 and trisomy 18. Pediatrics 2003; 111 (4 Pt 1) 777-784
• 23 McGraw MP, Perlman JM. Attitudes of neonatologists toward delivery room management of confirmed trisomy 18: potential factors influencing a changing dynamic. Pediatrics 2008; 121: 1106-1110
• 24 Kaneko Y, Kobayashi J, Achiwa I , et al. Cardiac surgery in patients with trisomy 18. Pediatr Cardiol 2009; 30: 729-734
• 25 Suzuki K, Yamaki S, Mimori S , et al. Pulmonary vascular disease in Down's syndrome with complete atrioventricular septal defect. Am J Cardiol 2000; 86: 434-437
• 26 Van Praagh S, Truman T, Firpo A , et al. Cardiac malformations in trisomy-18: a study of 41 postmortem cases. J Am Coll Cardiol 1989; 13: 1586-1597
• 27 Cooney TP, Thurlbeck WM. Pulmonary hypoplasia in Down's syndrome. N Engl J Med 1982; 307: 1170-1173
• 28 Yamaki S, Yasui H, Kado H , et al. Pulmonary vascular disease and operative indications in complete atrioventricular canal defect in early infancy. J Thorac Cardiovasc Surg 1993; 106: 398-405
• 29 Cappelli-Bigazzi M, Santoro G, Battaglia C , et al. Endothelial cell function in patients with Down's syndrome. Am J Cardiol 2004; 94: 392-395
• 30 Placidi S, Digilio MC, Marino B. Types of cardiac defects in children with Down's syndrome. Cardiol Young 2006; 16: 198-199 ; author reply 197
• 31 Kava MP, Tullu MS, Muranjan MN, Girisha KM. Down syndrome: clinical profile from India. Arch Med Res 2004; 35: 31-35
• 32 de Rubens Figueroa J, del Pozzo Magaña B, Pablos Hach JL, Calderón Jiménez C, Castrejón Urbina R. [Heart malformations in children with Down syndrome]. Rev Esp Cardiol 2003; 56: 894-899
• 33 Vida VL, Barnoya J, Larrazabal LA, Gaitan G, de Maria Garcia F, Castañeda AR. Congenital cardiac disease in children with Down's syndrome in Guatemala. Cardiol Young 2005; 15: 286-290
• 34 Maeda J, Yamagishi H, Furutani Y , et al. The impact of cardiac surgery in patients with trisomy 18 and trisomy 13 in Japan. Am J Med Genet A 2011; 155A: 2641-2646